Alkermes Plc. (ALKS) Files Form 4 Insider Selling : Elliot Ehrich Sells 5,000 Shares

Alkermes Plc. (ALKS): Elliot Ehrich , EVP, R&D & CMO, Alkermes, Inc. of Alkermes Plc. sold 5,000 shares on Sep 21, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $50.83 per share for a total value of $254,168.56 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 19, 2016, Elliot Ehrich (EVP, R&D & CMO, Alkermes, Inc.) sold 5,000 shares at $48.87 per share price.On Sep 7, 2016, Iain Michael Brown (SVP Finance & CAO, Alks Inc.) sold 29,976 shares at $46.11 per share price.Also, On Sep 7, 2016, David Joseph Gaffin (SVP, CLO, Alkermes, Inc.) sold 2,382 shares at $45.92 per share price.On Sep 7, 2016, Paul J Mitchell (director) sold 2,000 shares at $46.05 per share price.

Alkermes Plc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Alkermes Plc which led to swings in the share price. The shares opened for trading at $50.18 and hit $50.2318 on the upside , eventually ending the session at $49.77, with a gain of 0.16% or 0.08 points. The heightened volatility saw the trading volume jump to 10,15,835 shares. The 52-week high of the share price is $80.71 and the company has a market cap of $7,543 M . The 52-week low of the share price is at $27.14.

Alkermes Plc Money Flow Index Chart

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching developing and commercializing both with partners and on its own pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders such as addiction schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil ALKS 5461 ALKS 3831 ALKS 8700 and RDB 1419. The Company’s main marketed products include RISPERDAL CONSTA INVEGA SUSTENNA/XEPLION AMPYRA/FAMPYRA BYDUREON and VIVITROL.

Leave a Reply

Alkermes Plc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alkermes Plc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.